Asset profile
HRS-9057
Small molecule
Evidence outlook · lead readout
NCT06506994 · Heart Failure With Volume Overload
The completed lead evidence is positive, with design limits that temper confidence — see the rationale below for exactly which.
NCT06506994: Participants were randomized and an active comparator (tolvaptan) was used, but neither participants nor assessors were blinded and the study enrolled only 25 people, so subjective measures like edema and congestion scoring could be influenced by expectation. Its primary measure is also safety monitoring rather than a defined efficacy outcome, and no results have been posted yet.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.